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UNLABELLED: No data are available about the prediction of long-term survival
using repeated noninvasive tests of liver fibrosis in chronic hepatitis C (CHC). We
aimed to assess the prognostic value of 3-year liver stiffness measurement (LSM),
aspartate aminotransferase to platelet ratio index (APRI), and fibrosis 4 (FIB-4)
evolution in CHC. CHC patients with two LSM (1,000-1,500 days interval) were
prospectively included. Blood fibrosis tests APRI and FIB-4 were calculated the day
of baseline (bLSM) and follow-up (fLSM) LSM. Evolution of fibrosis tests was
expressed as delta: (follow-up-baseline results)/duration. Date and cause of death
were recorded during follow-up that started the day of fLSM. In all, 1,025 patients
were included. Median follow-up after fLSM was 38.0 months (interquartile range
[IQR]: 27.7-46.1) during which 35 patients died (14 liver-related death) and seven
had liver transplantation. Prognostic accuracy (Harrell C-index) of multivariate
models including baseline and delta results was not significantly different between
LSM and FIB-4 (P ≥ 0.24), whereas FIB-4 provided more accurate prognostic models
than APRI (P = 0.03). By multivariate analysis including LSM variables, overall
survival was independently predicted by bLSM, delta (dLSM), and sustained
virological response (SVR). Prognosis was excellent in patients having bLSM <7 kPa,
SVR, or no increase (<1 kPa/year) in 7-14 kPa bLSM. Prognosis was significantly
impaired in patients with an increase (≥ 1 kPa/year) in 7-14 kPa bLSM, or decrease
(≤ 0 kPa/year) in ≥ 14 kPa bLSM (P = 0.949 between these two groups). Patients
with an increase (>0 kPa/year) in ≥ 14 kPa bLSM had the worst prognosis. Baseline
and delta FIB-4 also identified patient subgroups with significantly different
prognosis.
CONCLUSION: Three-year evolution of noninvasive tests of liver fibrosis has a
strong prognostic value in CHC patients. These tests should be repeated to monitor
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